21-02-2018 | 16:21

Due to media requests and dissemination of incorrect information about the risks of pharmacies closure and growth of drug prices that allegedly may take place if the Ministry of Industry and Trade adopts a draft law allowing sale of over-the-counter drug by commercial organizations, FAS would like to report the following:


Under the draft law, a commercial organization can be involved in retail trade with over-the-counter drugs in accord with the Law on medicinal drugs turnover, that requests, in particular, to obtain a license for pharmacological operations.


Today, any person intended to pursue retail trade with medicinal drugs can get a relevant license. To obtain the license and further perform retail trade with over-the-counter drugs, a commercial organization as well as any pharmacy must observe a number of standards specified in the Regulations in licensing pharmaceutical operations.


Thus, the draft law does not provide for any preferences or simplified drug sale procedures for particular type of organizations, and adopting it will not bring radical changes to the market.


The retail drug market is very dynamic. Hundreds of sales points are opened and closed daily in Russia. The new law will have no impact upon the current trends, let alone becoming a cause of mass closure of pharmacies.


Concerns about a possible growth of prices in case of adopting the draft law also are unjustified. Prices for the drugs included in the list of vital and essential medicines are regulated by the government and do not experience sharp fluctuations. Moreover, FAS undertakes systemic efforts to reduce them.


The draft law will not impact prices for other drugs that are also in the focus of the regulators’ attention. If monopolistically high prices are fixed, FAS employs antimonopoly measures designed to reduce them. One of the latest examples is FAS case against “Novartis Pharma” Ltd that fixed monopolistically high prices for “Tyverb” oncological agent (“Lapatinib” International Non-Proprietary Name). Increasing the number of players on the retail drug market intensifies competition between them, which, on the contrary will stimulate market participants to reduce prices.

Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide